Difference between revisions of "I-123 Biomarker Committee"
Jump to navigation
Jump to search
m (→Round 6) |
m (→Round 6) |
||
| Line 21: | Line 21: | ||
==QIBA Funded Projects== | ==QIBA Funded Projects== | ||
| + | |||
====Round 6==== | ====Round 6==== | ||
| + | |||
*[[Media:Multi-center Phantom Study to Characterize Bias and Precision of Quantitative I-123 SPECT.pdf | Project (V) Multi-center Phantom Study to Characterize Bias and Precision of Quantitative I-123 SPECT (University of Michigan)]] | *[[Media:Multi-center Phantom Study to Characterize Bias and Precision of Quantitative I-123 SPECT.pdf | Project (V) Multi-center Phantom Study to Characterize Bias and Precision of Quantitative I-123 SPECT (University of Michigan)]] | ||
| − | *[[Media: | + | |
| + | *[[Media:I-123 DAT Scan Digital Reference Object Development.pdf | Project (X) I-123 DAT Scan Digital Reference Object Development (University of Washington)]] | ||
Revision as of 16:40, 25 March 2019
- Co-chairs: John Dickson, PhD; John Seibyl, MD
- Secretary: Julie Lisiecki
Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases
Recent Meetings/Call Summaries
Profile Development
Reference Materials
- QIBA SPECT I-123 Biomarker Committee Presentation (11.16.2018) John Seibyl, MD